{"prompt": "['Novartis', 'Confidential', 'Page 27', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '4. Patients who have ever required intubation for a severe asthma attack/exacerbation.', '5. Patients who have a clinical condition which is likely to be worsened by ICS', 'administration (e.g. glaucoma, cataract and fragility fractures) who are according to', \"investigator's medical judgment at risk participating in the study.\", '6.', 'Patients treated with a LAMA for asthma within 3 months prior to Visit 1.', '7. Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or', 'bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients', 'who are stable on treatment can be considered.', '8. Patients who have had a respiratory tract infection or clinical significant asthma worsening', 'as defined by Investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 201.', 'Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or', 'asthma worsening.', '9. Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic', 'sinusitis) which in the opinion of the investigator may interfere with the study evaluation', 'or optimal participation in the study.', '10. Patients with a history of chronic lung diseases other than asthma, including (but not', 'limited to) sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant', 'bronchiectasis and active tuberculosis.', '11. Patients with uncontrolled Type I or Type II diabetes.', '12. Patients who have a clinically significant laboratory abnormality at Visit 101.', '13. Use of other investigational drugs within 30 days or 5 half-lives of enrollment, until the', 'expected pharmacodynamics effect has returned to baseline, whichever is longer.', '14. Patients who, in the judgment of the investigator, have clinically significant condition', 'such as (but not limited to) unstable ischemic heart disease, New York Heart Association', '(NYHA) Class III/IV left ventricular failure, arrhythmia, uncontrolled hypertension,', 'cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other', 'neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune', 'diseases, hypokalemia, hyper adrenergic state, or ophthalmologic disorder or patients with', 'a medical condition that might compromise patient safety or compliance, interfere with', 'evaluation, or preclude completion of the study.', '15. Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with', 'persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months', 'and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel', 'blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be', 'considered for inclusion. In such patients, atrial fibrillation must be present at Visit 101', 'with a resting ventricular rate < 100/min.', '16. Patients with a history of myocardial infarction within 12 months prior to Visit 1.', '17. Concomitant use of agents known to prolong the QT interval unless it can be permanently', 'discontinued for the duration of study.', '18. Patients with a history of long QT syndrome or whose QTc measured at Visit 101', '(Fridericia method) is prolonged (> 450 msec for males and > 460 msec for females).', 'These patients should not be rescreened.']['Novartis', 'Confidential', 'Page 28', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '19. Patients who have a clinically significant ECG abnormality at Visit 101 (ECG evidence of', 'myocardial infarction at Visit 101 should be clinically assessed by the investigator with', 'supportive documentation).', '20. History of malignancy of any organ system (other than localized basal cell carcinoma of', 'the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless', 'of whether there is evidence of local recurrence or metastases.', '21. Patients with a history of hypersensitivity to lactose, any of the study drugs or its', 'excipients, or to similar drugs within the class including untoward reactions to', 'sympathomimetic amines or inhaled medication or any component thereof.', '22. Patients who have not achieved an acceptable spirometry result at Visit 101 (confirmed by', 'over read) and Visit 201 (spirometer) in accordance with ATS /ERS criteria for', 'acceptability and repeatability. (Repeat is allowed once for each visit, scheduled as close', 'as possible but not on the same day). If the patient fails the repeat assessment, the patient', 'may be rescreened once).', '23. Patients receiving any medications in the classes listed in Table 5-3.', '24. Patients receiving any asthma-related medications in the classes specified in Table 5-2.', '25. Patients receiving medications in the classes listed in Table 5-4 should be excluded unless', 'the medication has been stabilized for the specified period and the stated conditions have', 'been met.', '26. Patients on maintenance immunotherapy (desensitization) for allergies for less than 3', 'months prior to Visit 101 or patients on Maintenance Immunotherapy for more than 3', 'months prior to Visit 101 but expected to change throughout the course of the study.', '27. Patients who are serving a custodial sentence, do not have a permanent residence or who', 'are detained under local mental health legislation/regulations.', '28. Patients who are directly associated with any members of the study team or their family', 'members.', '29. Patients unable to use the Conceptl dry powder inhaler, Accuhaler\u00ae/Diskus\u00ae, Respimat\u00ae', 'or a metered dose inhaler. Spacer devices are not permitted for use with study treatment.', '30. History of alcohol or other substance abuse that based on judgement of the investigator', 'would interfere with study conduct.', '31. Patients with a known history of non-compliance to medication or who were unable to', 'complete a patient eDiary, use electronic Peak Flow Meter, or complete questionnaires', '(PROs).', '32. Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., inconsistent', 'night shift workers). Consistent night shift workers may be considered for inclusion.', '33. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female', 'after conception and until the termination of gestation, confirmed by a positive hCG', 'laboratory test.', '34. Women of child-bearing potential, defined as all women physiologically capable of', 'becoming pregnant, unless they are using highly effective methods of contraception', 'during dosing of study treatment and follow-up period.', 'Highly Effective contraception methods include:']\n\n###\n\n", "completion": "END"}